Submit an abstract
Abstract submission for the IDF Virtual Congress 2023 opens on June 1 and closes on July 31.
The IDF Virtual Congress 2023 welcomes original abstracts on the following topics related to diabetes complications and diabetes in emergency situations:
- Cardiovascular Disease
- Other Complications
- Diabetes and Covid-19
- Diabetes in crises: natural disaster and conflict
All accepted abstracts will be published in the IDF journal Diabetes Research and Clinical Practice (DRCP).
Submission mode: Abstract submission is only possible online through the IDF 2023 abstract submission portal (link available on June 1). Abstracts submitted by post, fax or email will NOT be accepted. The abstract submission portal will NOT be available after 31 July 2023.
IDF congress profile: In order to submit an abstract, a congress profile must be created, which gives access to the online abstract submission portal. The submitting author must ensure accurate contact details are entered. One or more abstracts can be submitted by logging in with a congress profile.
Submitting author/presenting author: If the submitting author is not also the presenting author, the submitting author is responsible for informing the presenting author of all communications received regarding the abstract.
Presenting author registration: The presenting author must be registered for the congress by 1 September 2023. If the presenting author is not registered by this date, their abstract will be REMOVED from the programme.
Number of submissions: There can only be ONE presenting author per abstract. The same abstract CANNOT be submitted multiple times by listing different presenting authors. An unlimited number of abstracts can be submitted by one author.
Language: All abstracts must be submitted in English. Should English not be your first language, you may wish to have your abstract examined by a fluent English speaker prior to submission.
Originality of abstracts: Work published in peer-reviewed journals before 4 December 2023 CANNOT be submitted to the IDF Virtual Congress 2023. Abstracts already presented at face-to-face meetings also CANNOT be submitted, unless there are new methods and/or findings. Abstracts already presented at a national virtual meeting can be resubmitted. However, previously submitted work CANNOT be resubmitted, if it was presented at an international virtual meeting.
Disclosure of interests: Any financial relationships with commercial entities related to the authors or products and processes described in the abstract must be appropriately disclosed.
Regulatory approval: The submitting author confirms that local regulatory approval has been obtained as required by local laws.
Author consent: The submitting author declares all authors have read and approved the submitted work.
Copyright transfer: Authors must attest that their submitted work does not infringe any copyright legislation. Copyright for the publication of abstracts is automatically transferred to the International Diabetes Federation upon submission and acceptance of the regulations within the online abstract submission portal. For rejected abstracts, the copyright reverts back to the authors.
Publication in DRCP: All accepted abstracts will be published in the online journal Diabetes Research and Clinical Practice (DRCP). The approximate publication date will be in April 2024. Please note that the accepted abstracts will be published as submitted through the IDF 2023 abstract submission portal. Any changes made to the digital poster submission will not be reflected in the DRCP publication. Abstracts cannot be removed or corrected once they are published in DRCP.
Topic: There are various categories that have been defined for the abstract programme within the four streams. Ensure that you select the MOST relevant topic that BEST describes the content of your abstract. Categories are used for reviewing and indexing purposes.
Abstract title: The title is limited to 120 characters including spaces and should be brief and relevant. Special characters should NOT be used in your title but spelt out instead (e.g. α should be written as alpha, β as beta). Only use standard abbreviations and generic drug names in the title.
Authors: Only 12 authors and/or study groups can be listed. Only one institution can be entered per author.
Abstract body: The abstract structure is laid out under the headings
Background, Aims, Method, Results, Conclusion and References.
Font size and style will be automatically configured by the system.
Tables: Maximum of 1 Table OR 1 Figure will be accepted in the submission field and count towards the character limit. Figures or Tables included in an abstract need to have a mention of this in the abstract text (e.g. Table or Figure 1). The character deduction for tables is not fixed and will be generated by the character count shown below the submission field. The table/figure must not contain more than 480 characters. The table must have a maximum of 10 columns and 12 rows. Figures must have a maximum of two panels. Images and photographs are NOT allowed.
The length of the abstract is limited to 2100 characters with spaces. Only the abstract body and any inserted tables count towards this word limit. The word count displayed beneath the submission field is final and indisputable.
Only commonly accepted abbreviations should be used (e.g. GDM, BMI, DM). Treatment groups or drug names should NOT be abbreviated. Less widely recognised abbreviations may be used if introduced on first usage (e.g. ambulatory blood pressure monitoring, ABPM).
Only approved and generic (non-proprietary) drug names should be used.
Do NOT enter the title, authors, or grant information into the abstract body, but you can include up to three references at the end of the abstract. References need to be numbered (reference number in square brackets) and must have a matching citation number (citation number in square brackets).
Selection and notification process
Selection: All submitted abstracts undergo a review process by the Programme Committee. Accepted abstracts are selected for oral poster presentation or e-poster gallery display. The Programme Committee reserves the right to accept or reject any submitted abstract and re-categorise any accepted abstract. The decision of the Programme Committee is final and irrevocable.
Notification: Notice of acceptance or rejection of submitted abstracts will be sent to submitting authors on 25 August 2023. It is the responsibility of the submitting author to inform all other authors of the status of the abstract. A submitting author may also check their congress profile to see the status of the abstract.
Continuing Medical Education (CME)
Applications for Continuing Medical Education (CME) accreditation for physicians and other healthcare professionals will be presented to the European Accreditation Council for Continuing Medical Education (EACCME). EACCME credits are recognised by the American Medical Association towards the Physician’s Recognition Award (PRA). It is expected that the IDF Virtual Congress 2023 will be accredited with approximately 15 hours of CME credits. CME certificates will be available after the congress.